REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
연구 개요
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- 스폰서
- 리드: 리제네론
- 적응증
- Cancer-Associated Thrombosis (CAT)
- 중재
- REGN7508, Placebo
- 목표 등록
- 1,120명
- 시작일
- 2026-03-09
- 완료(예정)
- 2030-05-06
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.